Send us a text

Will FDA rules disrupt the way we diagnose diseases? 

In this episode, I break down a seismic shift in lab medicine: a federal court has vacated the FDA’s controversial rule classifying lab-developed tests (LDTs) as medical devices. This change carries serious implications for innovation, digital pathology, AI-based diagnostics, and small labs across the U.S.

🎧 What You’ll Hear:

• What LDTs are and why they matter for rare diseases and personalized medicine
  
  
  
• Why the FDA rule sparked backlash from the pathology community
  
  
  
• What the court’s decision means for AI algorithms in digital pathology
  
  
  
• What’s next: Will Congress revive the VALID Act?
  
  
  
• How this affects labs, startups, and the future of diagnostic innovation
  
  
  

This podcast is packed with updates every pathology professional should know. 🔍

Support the show

Get the "Digital Pathology 101" FREE E-book and join us!